Cyclosporine's effect on canine pancreatic endocrine function
- PMID: 3289146
- DOI: 10.1097/00007890-198806000-00006
Cyclosporine's effect on canine pancreatic endocrine function
Abstract
This study was designed to investigate the mechanism, and reversibility, of glucose intolerance following the acute administration of cyclosporine (CsA) in a canine model. Three groups underwent a baseline intravenous glucose tolerance test (IVGTT; 0.5 g/kg of glucose), with simultaneous insulin determinations. In groups A and B, repeat IVGTTs were performed, at three-day intervals, after 2, 4, and 6 mg/kg of intravenous CsA + solvent (group A; n = 8), or the solvent alone (group B; n = 5). Repeat IVGTTs were performed in group A, 24 and 72 hr after the last CsA infusion. In group C (n = 5), IVGTTs were performed, 4, 24, 48, and 72 hr after oral CsA (12.5 mg/kg). In each group, the rate of glucose clearance (k value,--per cent min), and basal-to-peak insulin difference (uU/ml), for each IVGTT were compared with the baseline results. In group A, the basal-to-peak insulin difference was significantly lower than baseline (81.9 +/- 13.6) after 2 mg/kg (27.3 +/- 3.1; P less than 0.005), 4 mg/kg (22.7 +/- 3.7; P less than 0.001); and 6 mg/kg (16.8 +/- 3.2; P less than 0.001) of CsA, and returned to baseline within 24 hr (81.4 +/- 3.7). Corresponding K values were also significantly different in group A. In group B, there were no significant differences in these parameters from controls, at the equivalent doses of the solvent alone. At 4 hr after oral CsA (group C), there was a reduction in the basal-to-peak insulin difference (37.2 +/- 9.1 vs. 22.5 +/- 4.1) and K values (-3.20 +/- 0.4 vs. -1.96 +/- 0.3), with the change in K values being statistically significant (P less than 0.05). A return to baseline levels was present at 24 h. This study demonstrates that, in the canine model, therapeutic doses of intravenous and oral CsA acutely impair glucose regulation. This acute effect is secondary to decreased peripheral insulin levels, is reversible at 24 h, and is not evident with CsA solvent alone. The mechanism of decreased insulin secretion following CsA administration requires further elucidation.
Similar articles
-
Effects of cyclosporin on insulin and C-peptide secretion in healthy beagles.Diabetes. 1989 Jun;38(6):698-703. doi: 10.2337/diab.38.6.698. Diabetes. 1989. PMID: 2656339
-
Transplantation of purified single-donor canine islet allografts with cyclosporine.Transplantation. 1989 Apr;47(4):583-7. doi: 10.1097/00007890-198904000-00003. Transplantation. 1989. PMID: 2495586
-
Interference by cyclosporine with the endocrine function of the canine pancreas.Transplantation. 1987 Jul;44(1):13-6. doi: 10.1097/00007890-198707000-00004. Transplantation. 1987. PMID: 3299911
-
Inhibition of insulin release by cyclosporine and production of peripheral insulin resistance in the dog.Transplantation. 1990 Mar;49(3):600-4. doi: 10.1097/00007890-199003000-00023. Transplantation. 1990. PMID: 2180152
-
Cyclosporine's effect on insulin secretion in patients with kidney transplants.Transplantation. 1991 Sep;52(3):500-3. doi: 10.1097/00007890-199109000-00022. Transplantation. 1991. PMID: 1897023
Cited by
-
Endocrine and metabolic abnormalities following kidney transplantation.Klin Wochenschr. 1989 Sep 1;67(17):907-18. doi: 10.1007/BF01717348. Klin Wochenschr. 1989. PMID: 2681969 Review.
-
The pathophysiology of Sandimmune (cyclosporine) in man and animals.Pediatr Nephrol. 1990 Nov;4(6):686-704. doi: 10.1007/BF00858649. Pediatr Nephrol. 1990. PMID: 2088472 Review.
-
Corticosteroids in kidney transplant recipients. Safety issues and timing of discontinuation.Drug Saf. 1995 Sep;13(3):145-56. doi: 10.2165/00002018-199513030-00002. Drug Saf. 1995. PMID: 7495501 Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources